NextCell Pharma AB Cash Flow Conversion Efficiency

Latest as of August 2025: -0.162x

NextCell Pharma AB cash flow conversion efficiency. Based on the latest financial reports, NextCell Pharma AB (NXTCL) has a cash flow conversion efficiency ratio of -0.162x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.77 Million ≈ $-1.16 Million USD) by net assets (Skr66.39 Million ≈ $7.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of NextCell Pharma AB (2015–2025)

Cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025. This chart illustrates how NextCell Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NXTCL share price today for real-time trading data and today's change.

NextCell Pharma AB Cash Flow Conversion Ratio Explained

NextCell Pharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

NextCell Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NextCell Pharma AB ranked by their cash flow conversion efficiency. Also see NXTCL market cap overview for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Osia Hyper Retail Limited NSE:OSIAHYPER	-0.012x
Datadot Technology Ltd AU:DDT	-0.008x
Predilife PA:ALPRE	0.219x
H&T Group plc LSE:HAT	0.033x
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares NASDAQ:AZI	-0.029x
J-Star Holding Co., Ltd. Ordinary Shares NASDAQ:YMAT	0.351x
Pinnacle Minerals Ltd AU:PIM	-0.106x
Maple Peak Investments Inc V:MAP	-0.062x

Annual Cash Flow Conversion Efficiency for NextCell Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025. Review NXTCL free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr66.39 Million ≈ $7.14 Million	Skr-38.86 Million ≈ $-4.18 Million	-0.585x	-4.75%
2024-08-31	Skr67.60 Million ≈ $7.27 Million	Skr-37.78 Million ≈ $-4.07 Million	-0.559x	+3.43%
2023-08-31	Skr75.73 Million ≈ $8.15 Million	Skr-43.83 Million ≈ $-4.72 Million	-0.579x	-100.73%
2022-08-31	Skr115.54 Million ≈ $12.43 Million	Skr-33.31 Million ≈ $-3.58 Million	-0.288x	-69.19%
2021-08-31	Skr150.09 Million ≈ $16.15 Million	Skr-25.58 Million ≈ $-2.75 Million	-0.170x	+76.44%
2020-08-31	Skr26.22 Million ≈ $2.82 Million	Skr-18.96 Million ≈ $-2.04 Million	-0.723x	+24.99%
2019-08-31	Skr22.96 Million ≈ $2.47 Million	Skr-22.13 Million ≈ $-2.38 Million	-0.964x	+64.13%
2018-08-31	Skr5.04 Million ≈ $542.53K	Skr-13.55 Million ≈ $-1.46 Million	-2.688x	-246.01%
2017-08-31	Skr19.07 Million ≈ $2.05 Million	Skr-14.82 Million ≈ $-1.59 Million	-0.777x	+52.74%
2016-08-31	Skr6.76 Million ≈ $728.00K	Skr-11.12 Million ≈ $-1.20 Million	-1.644x	-106.93%
2015-08-31	Skr9.77 Million ≈ $1.05 Million	Skr-7.76 Million ≈ $-835.27K	-0.794x	--

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$3.43 Million

Skr31.91 Million SEK

Market Cap Rank

#29234 Global

#659 in Sweden

Share Price

Skr0.29

Change (1 day)

+13.02%

52-Week Range

Skr0.23 - Skr1.69

All Time High

Skr29.60